Checchi Capital Advisers LLC Takes Position in C.R. Bard, Inc. (BCR)
Checchi Capital Advisers LLC acquired a new position in shares of C.R. Bard, Inc. (NYSE:BCR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 832 shares of the medical instruments supplier’s stock, valued at approximately $263,000.
Other large investors have also made changes to their positions in the company. Fundsmith LLP raised its stake in shares of C.R. Bard by 2.1% in the first quarter. Fundsmith LLP now owns 2,553,141 shares of the medical instruments supplier’s stock worth $633,996,000 after buying an additional 52,272 shares in the last quarter. Granite Investment Advisors LLC raised its stake in shares of C.R. Bard by 14.3% in the first quarter. Granite Investment Advisors LLC now owns 33,276 shares of the medical instruments supplier’s stock worth $8,270,000 after buying an additional 4,159 shares in the last quarter. Buffington Mohr McNeal raised its stake in shares of C.R. Bard by 14.1% in the first quarter. Buffington Mohr McNeal now owns 7,545 shares of the medical instruments supplier’s stock worth $1,875,000 after buying an additional 930 shares in the last quarter. Huntington National Bank raised its stake in shares of C.R. Bard by 8.4% in the first quarter. Huntington National Bank now owns 16,411 shares of the medical instruments supplier’s stock worth $4,079,000 after buying an additional 1,278 shares in the last quarter. Finally, Chase Investment Counsel Corp raised its stake in shares of C.R. Bard by 13.7% in the first quarter. Chase Investment Counsel Corp now owns 8,614 shares of the medical instruments supplier’s stock worth $2,140,000 after buying an additional 1,038 shares in the last quarter. 77.14% of the stock is currently owned by institutional investors.
C.R. Bard, Inc. (NYSE BCR) opened at 320.30 on Thursday. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27. The firm has a market capitalization of $23.28 billion, a P/E ratio of 42.05 and a beta of 0.59. The company’s 50 day moving average price is $319.39 and its 200 day moving average price is $285.73.
C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. The business had revenue of $979.70 million for the quarter, compared to the consensus estimate of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. C.R. Bard’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.54 EPS. Analysts anticipate that C.R. Bard, Inc. will post $11.82 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were issued a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.32%. C.R. Bard’s dividend payout ratio is currently 13.67%.
WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/checchi-capital-advisers-llc-takes-position-in-c-r-bard-inc-bcr/1498634.html.
BCR has been the topic of a number of analyst reports. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $342.00 price objective on the stock in a report on Thursday, May 11th. BidaskClub lowered C.R. Bard from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Raymond James Financial, Inc. lowered C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a report on Wednesday, April 26th. Wells Fargo & Company lowered C.R. Bard from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 25th. Finally, Cowen and Company boosted their price target on C.R. Bard from $240.00 to $317.00 and gave the stock a “market perform” rating in a research note on Monday, April 24th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. C.R. Bard has an average rating of “Hold” and an average target price of $285.67.
In other news, insider John P. Groetelaars sold 23,687 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the transaction, the insider now owns 31,445 shares in the company, valued at approximately $10,022,464.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.80% of the stock is currently owned by company insiders.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.